Due to its short half-life, its solution must be prepared frequently and administered as a continuous intravenous infusion” Kopeć et al (2018).

Abstract:

Epoprostenol sodium is recommended for the treatment of high-risk patients with pulmonary arterial hypertension. The use of high doses of this drug has been associated with long-term survival. Due to its short half-life, its solution must be prepared frequently and administered as a continuous intravenous infusion. According to the prescribing information, a solution of a new thermostable form of epoprostenol (Veletri; Actelion Pharmaceuticals, Allschwil, Switzerland) can be administered at room temperature for 48 hours, provided the concentration is >15,000 ng/ml.

Reference:

Central venous catheter occlusion during chronic epoprostenol infusion

DOI: https://doi.org/10.1016/j.healun.2018.03.018